177 related articles for article (PubMed ID: 36314696)
1. Anti-PD1 Agents in the Treatment of Cutaneous Squamous Cell Carcinoma.
Niu W; Robertson C; Hilton D
Skinmed; 2022; 20(5):338-342. PubMed ID: 36314696
[TBL] [Abstract][Full Text] [Related]
2. A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption.
Rogers HW; Coldiron BM
J Am Acad Dermatol; 2009 Jul; 61(1):96-103. PubMed ID: 19539843
[TBL] [Abstract][Full Text] [Related]
3. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.
Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F
Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788
[TBL] [Abstract][Full Text] [Related]
4. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
[TBL] [Abstract][Full Text] [Related]
5. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
Ashraf S; Alsharedi M
Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
[TBL] [Abstract][Full Text] [Related]
6. Cemiplimab in advanced cutaneous squamous cell carcinoma.
Naik PP
Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
[TBL] [Abstract][Full Text] [Related]
7. Combined sentinel lymphadenectomy and mohs micrographic surgery for high-risk cutaneous squamous cell carcinoma.
Weisberg NK; Bertagnolli MM; Becker DS
J Am Acad Dermatol; 2000 Sep; 43(3):483-8. PubMed ID: 10954660
[TBL] [Abstract][Full Text] [Related]
8. [Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab].
Delaitre L; Martins-Héricher J; Truchot E; Denis D; Prophette B; Maillard H; Bénéton-Benhard N
Ann Dermatol Venereol; 2020 Apr; 147(4):279-284. PubMed ID: 31879092
[TBL] [Abstract][Full Text] [Related]
9. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of non-melanoma skin cancers of the cutaneous perioral and vermilion lip treated by Mohs micrographic surgery.
Queen D; Knackstedt T; Polacco MA; Collins LK; Lee K; Samie FH
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):305-311. PubMed ID: 30284728
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
[TBL] [Abstract][Full Text] [Related]
13. Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.
Stevenson ML; Wang CQ; Abikhair M; Roudiani N; Felsen D; Krueger JG; Pavlick AC; Carucci JA
JAMA Dermatol; 2017 Apr; 153(4):299-303. PubMed ID: 28259107
[TBL] [Abstract][Full Text] [Related]
14. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
[TBL] [Abstract][Full Text] [Related]
15. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Hernández-Guerrero T; Doger B; Moreno V
Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
[TBL] [Abstract][Full Text] [Related]
16. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
Lai FY; Clarke R; Cooper P; Stokes J; Calvert P
Case Rep Oncol; 2023; 16(1):1156-1165. PubMed ID: 37900839
[TBL] [Abstract][Full Text] [Related]
17. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
Ascierto PA; Schadendorf D
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
[TBL] [Abstract][Full Text] [Related]
18. Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab-Real-World Experience in the Global SARS-CoV-2 Pandemic.
Pabianek M; Lesiak A; Nejc D; Kuncman Ł; Narbutt J; Skibińska M; Ciążyńska M
Curr Oncol; 2022 Oct; 29(10):7794-7801. PubMed ID: 36290893
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy.
Fujimura T; Kambayashi Y; Tono H; Lyu C; Ohuchi K; Hashimoto A; Aiba S
Dermatol Ther; 2020 Jul; 33(4):e13672. PubMed ID: 32449226
[TBL] [Abstract][Full Text] [Related]
20. Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer -Basal Cell Carcinoma or Squamous Cell Carcinoma-Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study.
Miñano Medrano R; López Estebaranz JL; Sanmartin-Jiménez O; Garcés JR; Rodríguez-Prieto MA; Vilarrasa-Rull E; de Eusebio-Murillo E; Escutia-Muñoz B; Flórez-Menéndez Á; Artola-Igarza JL; Alfaro-Rubio A; Redondo P; Delgado-Jiménez Y; Sánchez-Schmidt JM; Allende-Markixana I; Alonso-Pacheco ML; García-Bracamonte B; de la Cueva-Dobao P; Navarro-Tejedor R; Ciudad-Blanco C; Carnero-González L; Vázquez-Veiga H; Cano-Martínez N; Ruiz-Salas V; Sánchez-Sambucety P; Botella-Estrada R; González-Sixto B; Martorell-Calatayud A; Gil P; Morales-Gordillo V; Toll-Abelló A; Ocerin-Guerra I; Mayor-Arenal M; Suárez-Fernández R; Sainz-Gaspar L; Descalzo MA; García-Doval I;
Actas Dermosifiliogr; 2022 May; 113(5):451-458. PubMed ID: 35431059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
